Guideliness for kras gene mutations testing in colorrectal cancer;Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

Revista Espanola de Patologia

Volumn 45, Issue 2, 2012, Pages 76-85

  Hernández Losa, Javier ^a   Sanz, Julián ^b   Landolfi, Stefania ^a   López Ríos, Fernando ^c   Palacios, José ^d   Bautista, María Dolores ^e   Díaz Rubio, Eduardo ^b   Tabernero, Josep ^a   García Foncillas, Jesús ^f   Ramón y Cajal, Santiago ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c Hospital Universitario Madrid Sanchinarro   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Colorrectal cancer; Determination of mutations; KRAS gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRACTICE GUIDELINE; PREDICTIVE VALUE; SHORT SURVEY;

EID: 84859445133     PISSN: 16998855     EISSN: 1988561X     Source Type: Journal    
DOI: 10.1016/j.patol.2011.11.005     Document Type: Short Survey

References (21)

1. Cunningham D., Atkin W., Lenz H.J., Lynch H.T., Minsky B., Nordlinger B., et al. Colorectal cancer. Lancet 2010, 375:1030-1047.
2. Cripps C., Gill S., Ahmed S., Colwell B., Dowden S., Kennecke H., et al. Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer. Curr Oncol 2010, 17:39-45.
3. Ochenduszko S.L., Krzemieniecki K. Targeted therapy in advanced colorectal cancer: More data, more questions. Anticancer Drugs 2010, 21:737-748.
4. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099.
5. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
7. Malumbres M., Barbacid M. RAS oncogenes: The first 30 years. Nat Rev Cancer 2003, 3:459-465.
8. Van Cutsem E, Lang I, Folprecht G, Nowacki M, Cascinu S, Shchepotin I, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS AND BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium 2010. Proceedings of ASCO GI 2010. 2010. 22-1-2010. Abstract 281.
9. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
10. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
11. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007, 25:4557-4561.
12. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
13. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
14. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
15. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
16. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de B.F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
17. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Schuch G, Zubel A, et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium 2010. Proceedings of ASCO GI 2010. 2010. 22-1-2010. Abstract 428.
18. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
19. Kohne C, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium 2010. Proceedings of ASCO GI 2010. 2010. 22-1-2010. Abstract 406.
20. Folprecht G., Gruenberger T., Bechstein W.O., Raab H.R., Lordick F., Hartmann J.T., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
21. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.